tiprankstipranks
Immunovant (IMVT)
NASDAQ:IMVT
US Market

Immunovant (IMVT) Income Statement

Compare
801 Followers

Immunovant Income Statement

Last quarter (Q2 2025), Immunovant's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Immunovant's net income was $-109.12M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 24Mar 23Mar 22Mar 21Mar 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -231.00K$ -1.32M$ -1.23M$ -998.00K$ -21.00K
Operating Expenses
$ 282.71M$ 208.28M$ 156.03M$ 108.12M$ 66.08M
Depreciation and Amortization
$ 231.00K$ 1.32M$ 1.23M$ 998.00K$ 21.00K
EBITDA
$ -269.98M$ -209.63M$ -155.58M$ -106.79M$ -65.64M
Operating Income
$ -282.71M$ -198.47M$ -156.16M$ -107.79M$ -65.67M
Other Income/Expenses
$ 23.94M$ -2.67M$ -781.00K$ 328.00K$ -2.51M
Pretax Income
$ -258.77M$ -210.95M$ -156.81M$ -107.79M$ -66.29M
Net Income
$ -259.34M$ -210.96M$ -156.73M$ -107.43M$ -66.39M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.88$ -1.71$ -1.43$ -1.22$ -1.54
Diluted EPS
$ -1.88$ -1.71$ -1.43$ -1.22$ -1.54
Weighted Average Shares Outstanding
138.10M 123.08M 109.68M 87.76M 43.20M
Weighted Average Shares Outstanding (Diluted)
138.10M 123.08M 109.68M 87.76M 43.20M
Currency in USD

Immunovant Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis